Cholinesterase inhibitors as chemical warfare agents: Community preparedness guidelines

Toxicology of Organophosphate & Carbamate Compounds

Volumn , Issue , 2006, Pages 47-68

  Watson, Annetta ^a   Bakshi, Kulbir ^b   Opresko, Dennis ^a   Young, Robert ^a   Hauschild, Veronique ^c   King, Joseph ^d  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b NATIONAL ACADEMY OF SCIENCES   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d US Army Environmental Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846782965     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088523-7/50006-5     Document Type: Chapter

References (151)

1. Aas P., Sterri S.H., Hjermstad S.H., Fonnum F. A method for generating vapors of soman: Toxicity of soman by inhalation in rats. Toxicol. Appl Pharmacol. 1985, 80:437-445.
2. Aas P., Veiteberg T.A., Fonnum F. Acute and sub-acute inhalation of an organophosphate induced alteration of cholinergic muscarinic receptors. Biochem. Pharmacol. 1987, 36:1261-1266.
3. Abernathy C.O., Roberts W.C. Risk assessment in the Environmental Protection Agency. J. Hazard. Mater. 1994, 39:135-142.
4. Abernathy C.O., Donohue J.M., Cicmanec J., Poirier K.A. Some comments on the selection of human intraspecies uncertainty factors. Hum. Ecol. Risk Assess. 2004, 10:29-37.
5. Abou-Donia M.B. The cytoskeleton as a target for organophosphorous ester-induced delayed neurotoxicity (OPIDN). Chem.-Biol. Interact. 1993, 87:383-393.
6. Albuquerque E.X., Santos M.D., Alkondon M., Pereira E.F., Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: A novel approach to the treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2001, 15(Suppl. 1):S19-S25.
7. American Conference of Governmental Industrial Hygienists 2002 TLVs and BEIs; Threshold limit values and biological exposure indices for chemical substances and physical agents 2002, American Conference of Governmental Industrial Hygienists, Cincinnati, OH.
8. Baker D.J., Sedgwick E.M. Single fibre electromyographic changes in man after organophosphate exposure. Hum. Exp. Toxicol. 1996, 15:369-375.
9. Bakry N.M., El-Rashidy A.H., Eldefawi A.T., Eldefawi M.E. Direct action of organophosphate anticholinesterases on nicotinic and muscarinic acetylcholine receptors. J. Biochem. Toxicol. 1988, 3:235-259.
10. Bakshi K.S., Pang S.N.J., Snyder R. Review of the Army's health risk assessments for oral exposure to six chemical-warfare agents. J. Toxicol. Environ. Health. (Part A) 2000, 59:281-526.
11. Bates H.K., LaBorde J.B., Dacre J.C., Young J.F. Developmental toxicity of soman in rats and rabbits. Teratology 1990, 42:15-23.
12. Benton B.J., Matson K.L., Crouse C.L., Forster J.S., Jakubowski E.M., Anthony J.S., Scotto J., Manthei J.H., Way R.A., Hulet S.W., Whalley C.E., Burnett D.C., Gavola B.I., Muse W.T., Miller D.B., Mioduszewski R.J., Thomson S.A. Low-level effects of VX vapor exposure on pupil size in rats. The Toxicologist 2004, 78(1-S).
13. Bramwell E.C.B., Ladell W.S.S., Shephard R.J. Human exposure to VX vapour. PTP 830 1963, Chemical and Biological Defence Establishment, Porton Down, Salisbury, Wiltshire, UK.
14. Britton K.B., Grant C.L. Prediction of octanol-water partition coefficients of organophosphates. Evaluation of structure-function relationships. Special Report 88-11 1988, U.S. Department of the Army, Corps of Engineers Cold Regions Research and Engineering Laboratory, Hanover, NH.
15. Bruckner J.V., Keys D.A., Fisher J.W. The acute exposure guideline (AEGL) program: Applications of physiologically based pharmacokinetic modeling. J. Toxicol. Environ. Health (Part A) 2004, 67:621-634.
16. Bucci T.J., Parker R.M. Toxicity studies on agents GB and GD (phase II): 90-day subchronic study of GB (sarin type II) in CD rats, Final report (DTIC: AD-A248618), E515 and E516 1992, Prepared by the National Center for Toxicological Research, Jefferson, AR, for the U.S. Department of the Army, Biomedical Research and Development Laboratory, Ft. Detrick, MD.
17. Bucci T.J., Parker R.M., Crowell J.A., Thurman J.D., Gosnell P.A. Toxicity studies on agents GB and GD (phase II): 90-day subchronic study of GB (sarin type I) in CD rats, FDA 224-85-0007 (DTIC: AD-A248617) 1991, Prepared by the National Center for Toxicological Research, Jefferson, AR for the U.S. Department of the Army, Biomedical Research and Development Laboratory, Ft. Detrick, MD.
18. Bucci T.J., Parker R.M., Crowell J.A., Thurman J.D., Gosnell P.A. Toxicity studies on agents GA (phase II): 90-day subchronic study of GA (tabun) in CD rats, Final report (DTIC: AD-A258042) 1992, Prepared by the National Center for Toxicological Research, Jefferson, AR, for the U.S. Department of the Army, Biomedical Research and Development Laboratory, Ft. Detrick, MD.
19. Bucci T.J., Parker R.M., Gosnell P.A. Toxicity studies on agents GB and GD (phase II): 90-day subchronic study of GD (soman) in CD rats, Final report (FDA 224-85-0007) 1992, Prepared by the National Center for Toxicological Research, Jefferson, AR, for the U.S. Department of the Army, Biomedical Research and Development Laboratory, Ft. Detrick, MD.
20. Bucci T.J., Fikes J.D., Parker R.M., Denny K.H., Dacre J.C. Developmental toxicity study (segment II: teratology) of tabun in CD rats and New Zealand white rabbits. Prepared for the U.S. Department of the Army 1993.
21. California Environmental Protection Agency Medical supervision. Pesticide and Safety Information Series A, No. HS-8 1998 September 20, Worker Health and Safety Branch, California Environmental Protection Agency, Department of Pesticide Regulation, Sacramento, CA.
22. Callaway S., Dirnhuber P. Estimation of the concentration of nerve agent vapour required to produce measured degrees of miosis in rabbit and human eyes. Technical Paper No. 64 1971, Chemical Defence Research Establishment, Porton Down Salisbury, Wiltshire, UK.
23. Carnes S.A. Disposing of chemical weapons: A desired end in search of an acceptable means. Environ. Prof. 1989, 11:279-290.
24. Carnes S.A., Watson A.P. Disposing of the U.S. chemical weapons stockpile: An approaching reality. J. Am. Med. Assoc. 1989, 262:653-659.
25. Chanda S.M., Lassiter T.L., Moser V.C., Barone S., Padilla S. Tissue carboxylesterases and chlorpyrifos toxicity in the developing rat. Hum. Ecol. Risk Assess. 2002, 8:75-90.
26. Chebabo S.R., Santos M.D., Albuquerque E.X. The organophosphate sarin, at low concentrations, inhibits the evoked release of GABA in rat hippocampal slices. Neurotoxicology 1999, 20:871-882.
27. Chemical Stockpile Emergency Preparedness Program Adoption of acute exposure guideline levels (AEGLs). Policy Paper No. 20 2003, (revised), Accessible through, Department of the Army and Federal Emergency Management Agency, Chemical Stockpile Emergency Preparedness Program. http://www.cseppplanners.net//CSEPP/hazard/hazard_aegl_policy_papers.asp x.
28. Cicmanec J.L., Dourson M.L., Hertzberg R.C. Noncancer risk assessment: Present and emerging issues. Toxicology and Risk Assessment: Principles, Methods, and Applications 1996, 293-310. Dekker, New York. A.M. Fan, L.W. Chang (Eds.).
29. Clark D.N. Review of reactions of chemical agents in water. AD-A213 287 1989, Defense Technical Information Center, Alexandria, VA.
30. Cohen B.S., Oberst F.W., Crook J.W., Harris C. Effect of repeated exposures of GB vapor on erythrocyte and brain cholinesterase in rats. Medical Laboratories Research Report No. 297 1954, Army Chemical Center, Aberdeen Proving Ground, MD.
31. Craig A.B., Woodson G.S. Observations on the effects of exposure to nerve gas: I. Clinical observations and cholinesterase depression. Am. J. Med. Sci. 1959, 238:13-17.
32. Crook J.W., Hott P., Owens E.J., Cummings E.G., Farrand R.L., Cooper A.E. The effects of subacute exposures of the mouse, rat, guinea pig, and rabbit to low-level VX concentrations. Technical Report ARCSL-TR-82038 1983, U.S. Army Armament Research and Development Command, Chemical Systems Laboratory, Aberdeen Proving Ground, MD.
33. Davies D.R., Holland P., Rumens M.J. The relationship between the chemical structure and neurotoxicity of alkyl organophosphorous compounds. Br. J. Pharmacol. 1960, 15:271-278.
34. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 1996, 14:334-336.
35. Davis W. The Serpent and the Rainbow 1985, Warner.
36. De Jong L.P.A., Wolring G.Z. Effect of 1-(AR)alkyl-2-hydroxyimino methyl-pyridium salts on reactivation and aging of acetylcholinesterase inhibited by ethyl dimethylphosphor-amidocyanidate (tabun). Biochem. Pharmacol. 1978, 27:2229-2235.
37. Denk J.R. Effects of GB on mammalian germ cells and reproductive performance. EB-TR-74087 1975, U.S. Department of the Army, Edgewood Arsenal, Aberdeen Proving Ground, MD.
38. Department of the Army Chemical agent data sheets, Vol. 1, Edgewood Arsenal Special Report EO-SR-74001 1974, U.S. Department of the Army, Edgewood Arsenal, Aberdeen Proving Ground, MD.
39. Department of the Army Final programmatic environmental impact statement for the Chemical Stockpile Disposal Program 1988, U.S. Department of the Army, Office of the Program Executive Officer, Program Manager for Chemical Demilitarization, Aberdeen Proving Ground, MD.
40. Department of the Army Occupational health guidelines for evaluation and control of occupational exposure to nerve agents GA, GB, GD and VX, DA Pam 40-8 1990, U.S. Department of the Army, Washington, DC.
41. Department of the Army Potential military chemical/biological agents and compounds. Field Manual FM 3-9 (NAVFAC P-467, AFR 355-7) 1990, Headquarters, Departments of the Army, Departments of the Navy, Washington, DC.
42. Department of the Army Material safety data sheets: Lethal nerve agents GA, GB, VX 1992, U.S. Department of the Army, Edgewood Research, Development and Engineering Center, Aberdeen Proving Ground, MD.
43. De WolffF.A., Treijtel N., Vermeulen M. Mechanisms of peripheral neurotoxicity. Site-Selective Neurotoxicity 2002, 282-303. Taylor & Francis, New York. D.S. Lester, W. Slikker, P. Lazarovici (Eds.).
44. Dourson M.L. Methods for estimating oral reference doses (RfDs). Risk Assessment of Essential Elements 1994, 51-61. ILSI Press, Washington, DC. W. Mertz, C.O. Abernathy, S.S. Olin (Eds.).
45. Dourson M.L., Charnley G., Scheuplein R., Barkhurst M. Differential sensitivity of children and adults to chemical toxicity. Hum. Ecol. Risk Assess 2004, 10:21-27.
46. Dunn M.A., Sidell F.R. Progress in the medical defense against nerve agents. J. Am. Med. Assoc. 1989, 262:649-652.
47. Dutreau C.W., McGrath F.P., Bray E.H. Toxicity studies on GD. 1. Median lethal concentration by inhalation in pigeons, rabbits, rats, and mice. 2 Median detectable concentration by odor for man. MDRR 8, CMLEM-52 (ADE 470029 058) 1950, Chemical Corps, Medical Division, Army Chemical Center, MD.
48. Ehrich M., Jortner B.S. Organophosphorous-induced delayed neuropathy. Handbook of Neurotoxicity 2002, Vol.1:17-25. Humana Press, Totowa, NJ. E.J. Massaro (Ed.).
49. Fairley A., Mumford S.A. Detection of the G gases by smell. PTP 74 1948, Chemical Defence Research Establishment, Porton Down, Salisbury, Wiltshire, UK.
50. Goldman M., Klein A.K., Kawakami T.G., Rosenblatt L.S. Toxicity studies on agents GB and GD, DTIC (AD A187841). Laboratory for Energy-Related Health Research, prepared for the U.S. Department of the Army, Medical Research and Development Command 1987.
51. Goldman M., Wilson B.W., Kawakami T.G., Rosenblatt L.S., Culberson M.R., Schreider J.P., Remsen J.F., Shifrine M. Toxicity studies on agent VX, DTIC (AD A201397). Laboratory for Energy-Related Health Research, prepared for the U.S. Department of the Army, Medical Research and Development Command 1988.
52. Goldstein B.D. Changes in spinal cord reflexes following subchronic exposure to soman and sarin. Toxicol. Lett. 1989, 47:1-8.
53. Goldstein B.D., Fincher D.R., Searle J.R. Electrophysiological changes in the primary sensory neuron following subchronic soman and sarin: Alterations in sensory receptor function. Toxicol. Appl. Pharmacol. 1987, 91:55-64.
54. Gordon J.H., Inns R.H., Johnson M.K., Leadbeater L., Maidment M.P., Upshall D.G., Cooper G.H., Rickard R.L. The delayed neuropathic effects of nerve agents and some other organophosphorus compounds. Arch. Toxicol. 1983, 52:71-82.
55. Grob D., Harvey J.C. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J. Clin. Invest. 1958, 37:350-368.
56. Harris H., Whittaker M. The serum cholinesterase variants: Study of twenty-two families selected via the "intermediate" phenotype. Ann. Hum. Genet. 1962, 26:59-72.
57. Harris L.W., Heyl W.C., Stitcher D.L., Broomfield C.A. Effects of 1,1-oxydimethylene-bis-(4-tert-butyl pyridinium chloride) (SAD-128) and decamethonium on reactivation of soman- and sarin-inhibited cholinesterase by oximes. Biochem. Pharmacol. 1978, 27:757-761.
58. Harris R., Paxman J. A Higher Form of Killing: The Secret Story of Chemical and Biological Warfare 1982, Hill & Wang, New York.
59. Harvey J.C. Clinical observations on volunteers exposed to concentrations of GB. Medical Laboratories Research Report No. 114, Publication Control No. 5030-114 (CMLRE-ML-52) 1952, Medical Laboratories, Army Chemical Center, MD.
60. Holmstedt B. Pharmacology of organophosphorous cholinesterase inhibitors. Pharmacol. Rev. 1959, 11:567-688.
61. Holmstedt B. Structure-activity relationships of the organophosphorous anticholinesterase agents. Cholinesterases and Anticholinesterase Agents 1963, 428-485. Springer-Verlag, Berlin. G.B. Koelle (Ed.).
62. Husain K., Vijayaraghavan R., Pant S.C., Raza S.K., Pandey K.S. Delayed neurotoxic effect of sarin in mice after repeated inhalation exposure. J. Appl. Toxicol. 1993, 13:143-145.
63. Husain K., Pant S.C., Raza S.K., Singh R., Das Gupta S. A comparative study of delayed neuropathy in hens following repeated administration of organophosphorous compounds. Indian J. Physiol. Pharmacol. 1995, 39:47-50.
64. Jimmerson V.R., Shih T.-M., Mailman R.B. Variability in soman toxicity in the rat: Correlation with biochemical and behavioral measures. Toxicology 1989, 57:241-254.
65. Johns R.J. The effect of low concentrations of GB on the human eye. Research Report No. 100, Publication Control No. 5030-100 (CMLRE-ML-52) 1952, Chemical Corps Medical Laboratories, Army Chemical Center, MD.
66. Koelle G.B. Anticholinesterase agents. The Pharmacological Basis of Therapeutics 1975, 445-466. Macmillan, New York. 5th ed. L.S. Goodman, A. Gilman (Eds.).
67. Koelle G.B. Organophosphate poisoning-An overview. Fundam. Appl. Toxicol. 1981, 1:129-134.
68. Koelle G.B. Pharmacology of organophosphates. J. Appl. Toxicol. 1994, 14:105-109.
69. Koplovitz I., Harris W., Anderson D.R., Lennox W.J., Stewart J.R. Reduction by pryidostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of sarin and VX poisoning in rodents. Fundam. Appl. Toxicol. 1992, 18:102-106.
70. Krewski D., Bakshi K., Garrett R., Falke E., Rusch G., Gaylor D. Development of acute exposure guideline levels for airborne exposures to hazardous substances. Regul. Toxicol. Pharmacol. 2004, 39:184-201.
71. Laborde J.B., Bates H.K. Developmental toxicity study of agent GB-DCSM types I and II in CD rats and NZW rabbits. Final Report, AD-A168 331 1986, National Center for Toxicological Research, Jefferson, AR.
72. LaBorde J.B., Bates J.K., Dacre J.C., Young J.F. Developmental toxicity of sarin in rats and rabbits. J. Toxicol. Environ. Health 1996, 47:249-265.
73. Lallement G., Carpenteir P., Pernot-Marino I., Baubichon D., Collet A., Blanchet G. Involvement of the different rat hippocampal glutamatergic receptors in development of seizures induced by soman. Neurotoxicology 1991, 4:655-664.
74. Lallement G., Carpenteir P., Collet A., Pernot-Marino I., Baubichon D., Blanchet G. Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus. Brain Res 1991, 563:234-340.
75. Lehmann H., Liddell J. Human cholinesterase genetic variants and their recognition. Br. J. Anaesth. 1969, 41:235-244.
76. Lenz D.E., Maxwell D.M., Austin L.W. Development of a rat model for subacute exposure to the toxic organophosphate VX. J. Am. Coll. Toxicol. 1996, 15(Suppl. 2):S69-S77.
77. Lillibridge S. United States Medical Delegation to Japan 1995, Trip Report (25 April 1995). From S. R. Lillibridge, Acting Chief, Disaster Assessment and Epidemiology Section to R.J. Jackson, Director, National Center for Environmental Health, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA.
78. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., Zerlin M. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatr. 2001, 49:279-288.
79. Marrs T.C., Maynard R.L., Sidell F.R. Chemical Warfare Agents; Toxicology and Treatment 1996, Wiley, Chichester, UK.
80. Maxwell D.M. The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds. Toxicol. Appl. Pharmacol. 1992, 114:306-312.
81. McGrath F.P., Von Berg V.J., Oberst F.W. Toxicity and perception of GF vapor. MLRR 185 1953, Medical Laboratory, Army Chemical Center, MD.
82. McKee W.H.E., Woolcott B. Report on exposures of unprotected men and rabbits to low concentrations of nerve gas vapour. PRP-143 1949, Chemical Defence Research Establishment, Porton Down, Salisbury, Wiltshire, UK.
83. Mehl A., Schenke T.M., Johnsen B.J., Fonnum F. The effects of trichlorfon and other organophosphates on prenatal brain development in the guinea pig. Neurochem. Res. 1994, 19:569-574.
84. Ministry of Defense Detection of G gases by smell 1996, (as cited in Marrs et al., 1996)., Ministry of Defense, UK.
85. Mioduszewski R.J., Reutter S.A., Miller L.L., Olajos E.J., Thomson S.A. Evaluation of airborne exposure limits for G-agents: Occupational and general population exposure criteria. ERDEC-TR-489 1998, Edgewood Research Development and Engineering Center, Aberdeen Proving Ground, MD.
86. Mioduszewski R.J., Manthei J., Way R., Burnett D., Gaviola B., Muse W., Thomson S., Sommerville D., Crosier R. Estimating the probability of sarin vapor toxicity in rats as a function of exposure concentration and duration. Proceedings of the International Chemical Weapons Demilitarization Conference 2000.
87. Mioduszewski R.J., Manthei J., Way R., Burnett D., Gaviola B., Muse W., Anthony J., Durst D., Sommerville D., Crosier R., Thomson S., Crouse C. ECBC low level operational toxicology program: Phase I-Inhalation toxicity of sarin vapor in rats as a function of exposure concentration and duration. ECBC-TR-183 2001, Edgewood Research Development and Engineering Center, Aberdeen Proving Ground, MD.
88. Mioduszewski R.J., Manthei J., Way R., Burnett D., Gaviola B., Muse W., Thomson S., Sommerville D., Crosier R., Scotto J., McCaskey D., Crouse C., Matson K. Low-level sarin vapor exposure in rats: Effect of exposure concentration and duration on pupil size. ECBC-TR-235 2002, Edgewood Chemical Biological Center, U.S. Army Soldier and Biological Chemical Command, Aberdeen Proving Ground, MD.
89. Mioduszewski R.J., Manthei J., Way R., Burnett D., Gaviola B., Muse W., Thomson S., Sommerville D., Crosier R. Interaction of exposure concentration and duration in determining acute toxic effects of sarin vapor in rats. Toxicol. Sci. 2002, 66:176-184.
90. Morgan D.P. Recognition and Management of Pesticide Poisoning 1989, EPA-540/9-88-001, U.S. Environmental Protection Agency, Washington, DC. 4th ed.
91. Morita H., Yanagisawa N., Nakajima T., Shimizu M., Hirabayashi H., Okudera H., Nohara M., Midorikawa Y., Mimura S. Sarin poisoning in Matsumoto, Japan. Lancet 1995, 346:290-293.
92. Munro N.B., Ambrose K.R., Watson A.P. Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: Implications for public protection. Environ. Health Perspect. 1994, 102:18-38.
93. National Research Council Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances 1993, National Academy Press, Washington, DC.
94. National Research Council, Committee on Toxicology, Subcommittee on Chronic Reference Dose for Chemical Warfare Agents Review of the U.S. Army's Health Risk Assessment for Oral Exposure to Six Chemical Warfare Agents 1999, National Academy Press, Washington, DC.
95. National Research Council Committee on Toxicology, Subcommittee on Acute Exposure Guideline Levels Acute Exposure Guideline Levels for Selected Airborne Chemicals 2000, Vol. 1. National Academy Press, Washington, DC.
96. National Research Council, Committee on Toxicology, Subcommittee on Acute Exposure Guideline Levels Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals 2001, National Academy Press, Washington, DC.
97. National Research Council, Committee on Toxicology, Subcommittee on Acute Exposure Guideline Levels Acute Exposure Guideline Levels for Selected Airborne Chemicals 2002, Vol. 2. National Academy Press, Washington, DC.
98. National Research Council, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences Acute Exposure Guideline Levels for Selected Airborne Chemicals 2003, Vol. 3. National Academies Press, Washington, DC.
99. National Research Council, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences Acute Exposure Guideline Levels for Selected Airborne Chemicals 2004, Vol. 4. National Academies Press, Washington, DC.
100. United States policy on chemical warfare program and bacteriological/biological research program. National Security Decision Memorandum 35 1969, National Security Council, Washington, DC.
101. Oberst F.W., Koon W.S., Christensen M.K., Crook J.W., Cresthull P., Freeman G. Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man. Clin. Pharmacol. Ther. 1968, 9:421-427.
102. Office of the Army Surgeon General Chronic toxicological criteria for chemical warfare compounds. Memorandum MCHB-CG-PPM 2000, U.S. Department of the Army, Office of the Surgeon General, Falls Church, VA.
103. Office of the Assistant Secretary of the Army Derivation of health-based environmental screening levels (HBESL) for chemical warfare agents 1999, Memorandum signed by Raymond J. Fatz, Deputy Assistant Secretary of the Army, 28 May 1999, Department of the Army, Office of the Assistant Secretary (Environment, Safety, and Occupational Health), Army Pentagon, Washington, DC.
104. Okumura T., Takasu N., Ishimatu S., Miyanoki S., Mitsuhashi A., Kumada K., Tanaka K., Hinohara S. Report on 640 victims of the Tokyo subway sarin attack. Ann. Emerg. Med. 1996, 28:129-135.
105. Opresko D.M., Young R.A., Faust R.A., Talmage S.S., Watson A.P., Ross R.H., Davidson K.A., King J. Chemical warfare agents: Estimating oral reference doses. Rev. Environ. Contam. Toxicol. 1998, 156:1-183.
106. Opresko D.M., Young R.A., Watson A.P., Faust R.A., Talmage S.S., Ross R.H., Davidson K.A., King J., Hauschild V. Chemical warfare agents: Current status of oral reference doses. Rev. Environ. Contam. Toxicol. 2001, 172:65-85.
107. Opresko D., Watson A., Young R. Nerve agents. Acute Exposure Guideline Levels for Selected Airborne Chemicals 2003, Vol. 3:15-300. National Academies Press, Washington, DC.
108. Pope C. Organophosphorous pesticides: Do they all have the same mechanism of toxicity?. J. Toxicol. Environ. Health (Part B) 1999, 2:161-181.
109. Pope C., Liu J. Nonesterase actions of anticholinesterase insecticides. Handbook of Neurotoxicology 2002, Vol. 1:29-43. Humana Press, Totowa, NJ. E.J. Massaro (Ed.).
110. Rao K.S., Aracava Y., Rickett D.L., Albuquerque E.X. Noncompetitive blockade of the nicotinic acetylcholine receptor-ion channel complex by an irreversible cholinesterase inhibitor. J. Pharmacol. Exp. Ther. 1987, 240:337-344.
111. Rice G.B., Lambert T.W., Haas B., Wallace V. Effect of chronic ingestion of VX on ovine blood cholinesterase. DTC 71-512 1971, Deseret Test Center, Dugway Proving Ground, Dugway, UT.
112. Robinson J.P. Chemical warfare. Sci. J. 1967, 4:33-40.
113. Rocha E.S., Chebabo S.R., Santos M.D., Aracava Y., Albuquerque E.X. An analysis of low level doses of cholinesterase inhibitors in cultured neurons and hippocampal slices of rats. Drug Chem. Toxicol. 1998, 21(Suppl. 1):191-200.
114. Rocha E.S., Santos M.D., Chebabo S.R., Aracava Y., Albuquerque E.X. Low concentrations of the organophosphate VX affect spontaneous and evoked transmitter release from hippocampal neurons: Toxicological relevance of cholinesterase-dependent actions. Toxicol. Appl. Pharmacol. 1999, 159:31-40.
115. Rubin L.S., Goldberg M.N. Effect of sarin on dark adaptation in man: Threshold changes. J. Appl. Physiol. 1957, 11:439-444.
116. Rubin L.S., Krop S., Goldberg M.N. Effect of sarin on dark adaptation in man: Mechanism of action. J. Appl. Physiol. 1957, 11:445-449.
117. Schreider J.P., Rowland J.R., Rosenblatt L.S., Hendrick A.G. The teratology effects of VX in rats, draft final report 1984, Prepared by the Laboratory for Energy-Related Health Effects Research, University of California, Davis, for the U.S. Army Medical Bioengineering Research and Development Laboratory, Ft. Detrick, MD.
118. Schreider J.P., Remsen J.F., Shifrine M. Toxicity studies on agent VX, Final report (AD A201397) 1988, Prepared by the Laboratory for Energy-Related Health Effects Research, University of California, Davis, for the U.S. Department of the Army, Medical Research and Development Command, Ft. Detrick, MD.
119. Sidell F.R. Clinical considerations in nerve agent intoxication. Chemical Warfare Agents 1992, 155-194. Academic Press, New York. S.M. Somani (Ed.).
120. Sidell F.R. Chemical agent terrorism. Ann. Emerg. Med. 1996, 28:223-224.
121. Sidell F.R. Nerve agents. Medical Aspects of Chemical and Biological Warfare 1997, 129-179. Office of the Surgeon General, Walter Reed Army Medical Center, Washington, DC. F.R. Sidell, E.T. Takafuji, D.R. Franz (Eds.).
122. Sidell F.R., GroffW.A. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol. Appl. Pharmacol. 1974, 27:241-252.
123. Sidell F.R., Kaminskis A. Temporal intrapersonal physiological variability of cholinesterase activity in human plasma and erythrocytes. Clin. Chem. 1975, 21:1961-1963.
124. Singer A.W., Jaax N.K., Graham J.S., McLeod C.G. Cardiomyopathy in soman and sarin intoxicated rats. Toxicol. Lett. 1987, 36:243-249.
125. Somani S.M., Solana R.P., Dube S.N. Toxicodynamics of nerve agents. Chemical Warfare Agents 1992, 67-123. Academic Press, New York. S.M. Somani (Ed.).
126. Spruit H.E., Langenberg J.B., Trap H.C., Van der Wiel H.J., Helmich R.B., van Helden H.P., Benschop H.P. Intravenous and inhalation toxicokinetics of sarin stereoisomers in atropinized guinea pigs. Toxicol. Appl. Pharmacol. 2000, 169:249-254.
127. Stockholm International Peace Research Institute CB Weapons today. The Problem of Chemical and Biological Warfare 1973, Vol. 2. Humanities Press, New York.
128. Storm J.E., Rozman K.K., Doull J. Occupational exposure limits for 30 organophosphate pesticides based on inhibition of red blood cell cholinesterase. Toxicology 2000, 150:1-29.
129. Ten Berge W.F., Zwart A., Appelman L.M. Concentration-time mortality response relationship of irritant and systemically acting vapours and gases. J. Hazard. Materials 1986, 13:301-309.
130. Thienes C.H., Haley T.J. Clinical Toxicology 1972, 95-115. Lea & Febiger, Philadelphia.
131. U.S. Army Center for Health Promotion and Preventive Medicine Derivation of Health-Based Environmental Screening Levels for Chemical Warfare Agents: A Technical Evaluation 1999, U.S. Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD.
132. U.S. Department of Health and Human Services Final recommendations for protecting the health and safety against potential adverse effects of long-term exposure to low doses of agents GA, GB, VX, Mustard agent (H, HD, T), and Lewisite (L). Fed. Reg. 1988, 53:8504-8507. Centers for Disease Control and Prevention.
133. U.S. Department of Health and Human Services Final recommendations for protecting human health from potential adverse effects of exposure to agents GA (Tabun), GB (Sarin), and VX. Fed. Reg. 2003, 68:58348-58351. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
134. U.S. Environmental Protection Agency Risk assessment guidance for Superfund: Vol. 1. Human health evaluation manual (part A). EPA/540/1-89/002 1989, Office of Emergency and Remedial Response, U.S. Environmental Protection Agency, Washington, DC.
135. U.S. Environmental Protection Agency Methods for the derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-90/066F 1994, Office of Health and Environmental Assessment, National Center for Environmental Assessment, Cincinnati, OH.
136. U.S. Environmental Protection Agency Health effects test guidelines: OPPTS 870.6100. Acute and 28-day delayed neurotoxicity of organophosphorous substances. EPA 712-C-98-237 1998, Office of Prevention, Pesticides and Toxic Substances, U.S. Environmental Protection Agency, Washington, DC.
137. U.S. Environmental Protection Agency Office of Pesticide Programs science policy on the use of data on cholinesterase inhibition for risk assessment of organophosphorus and carbamate pesticides 2000, Office of Pesticide Programs, U.S. Environmental Protection Agency, Washington, DC.
138. Van der Schans B.J., Lander B.J., Van der Wiel H., Langenberg J.P., Benshop H.P. Toxicokinetics of the nerve agent (±)-VX in anesthetized and stropinized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol. Appl. Pharmacol. 2003, 191:48-62.
139. Van Helden H.P.M., Langenberg J.P., Benschop H.P. Low level exposure to GB vapor in air: Diagnosis/dosimetry, lowest observable effect levels, and performance incapacitation, Award No. DAMD17-97-1-7360, final report 2001, Prepared by TNO Prins Maurits Laboratory, Rijswijk, The Netherlands, for the U.S. Army Medical Research and Materiel Command, Ft. Detrick, MD.
140. Van Helden H.P.M., Trap H.C., Kuijpers W.C., Groen B., Oostdijk J.P., Vanwersch R.A.P., Philippens I.H.C., Langenberg J.P., Benschop H.P. Low level exposure to GB vapor in air: Diagnosis/dosimetry, lowest observable effect level, and performance-incapacitation. RTO-MP-075, AC/323 (HFM-060) TP/37 2002, North Atlantic Treaty Organisation Research and Technology Organisation, Neuilly sur Seine Cedex, France.
141. Van Helden H.P.M., Trap H.C., Oostdijk J.P., Kuipers W.C., Langenberg J.P., Benschop H.P. Long-term, low-level exposure of guinea pigs and marmosets to sarin vapor in air: Lowest-observable-adverse-effect level. Toxicol. Appl. Pharmacol. 2003, 189:170-179.
142. Van Helden H.P.M., Trap H.C., Kuipers W.C., Oostdijk J.P., Benschop H.P., Langenberg J.P. Low-level exposure of guinea pigs and marmosets to sarin vapour in air: Lowest-observable-adverse-effect level (LOAEL) for miosis. J. App. Toxicol. 2004, 24:59-68.
143. Van Kampen K.R., Shupe J.L., Johnson A.E., James L.F., Smart R.A., Rasmussen J.E. Effects of nerve gas poisoning in sheep in Skull Valley, UT. J. Am. Vet. Med. Assoc. 1970, 156:1032-1035.
144. Watson A., Opresko D., Young R., Hauschild V. Development and application of acute exposure guideline levels (AEGLs) for chemical warfare nerve and sulfur mustard agents. J. Toxicol. Environ. Health. 2006, 9(Part B). (2): (Inpress).
145. Weimer J.T., McNamara B.P., Owens E.J., Cooper J.G., van de Wal A. Proposed revision of limits for human exposure to GB vapor in nonmilitary operations based on one-year exposures of laboratory animals to low airborne concentrations. ARCSL-TR-78056 1979, U.S. Army Armament Research and Development Command, Chemical Systems Laboratory, Aberdeen Proving Ground, MD.
146. Whalley C.E., Benton B.J., Manthei J.H., Way R.A., Jakubowski E.M., Burnett D.C., Gaviola B.P., Crosier R.B., Sommerville D.R., Muse W.T., Forster J.S., Mioduszewski R.J., Scotto J.A., Miller D.B., Crouse C.L., Matson K.L., Edwards J.L., Thomson S.A. Low-level cyclosarin (GF) vapor exposure in rats: Effect of exposure concentration and duration on pupil size. ECBC-TR-407S (081004) 2004, U.S. Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD.
147. Willems J.L., Narcaise M., DeBisschop H.C. Delayed neuropathy by the organophosphorous nerve agents soman and tabun. Arch. Toxicol. 1984, 55:76-77.
148. Wills J.H. The measurement and significance of changes in the cholinesterase activities of erythrocytes and plasma in man and animals. Crit. Rev. Toxicol. 1972, 1:153-202.
149. Wilson B.W., Henderson J.D., Kellner T.P., Goldman M., Higgins R.J., Dacre J.C. Toxicity of repeated doses of organophosphorous esters in the chicken. J. Toxicol. Environ. Health 1988, 23:115-126.
150. Wilson B.W., Kawakami T.G., Cone N., Henderson J.D., Rosenblatt L.S., Goldman M. Genotoxicity of the phosphoramidate agent tabun (GA). Toxicology 1994, 86:1-12.
151. Young R.A., Opresko D.M., Watson A.P., Ross R.H., King J., Choudhury H. Deriving toxicity values for organophosphorous nerve agents. A position paper in support of the procedures and rationale for deriving oral RfDs for chemical warfare agents. Hum. Ecol. Risk Assess. 1999, 5:589-634.